Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geovax Labs (NQ: GOVX )

8.350 +2.670 (+47.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Geovax Labs

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks — GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor
Via Investor Brand Network
Exposures COVID-19
Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Labs CEO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs. 
Via MarketBeat
Exposures COVID-19
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Provides First Half 2024 Business Update
Via NewMediaWire
GeoVax to Present at BIO International Convention 2024
Via TheNewswire.com
Exposures COVID-19
GeoVax to Present Data on GEO-CM04S1, A Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Company to Discuss Recent BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine and Provide Progress Update Across Its Clinical Development Pipeline 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
GeoVax to Present at BIO International Convention 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - May 17, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate 
Via TheNewswire.com
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
GeoVax to Host Conference Call at 4:30 PM ET 
Via TheNewswire.com
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress 
Via TheNewswire.com
Exposures COVID-19
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.